Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. filings document the operating results, governance and capital structure of a public kidney care and dialysis services company. Its 8-K reports furnish quarterly financial results, including revenue, operating income, per-share results, cash flow measures, treatment economics and share repurchase activity.
Proxy filings cover board matters, executive compensation, shareholder voting items and governance disclosures. Other current reports record material financing arrangements, amendments to secured credit facilities, share repurchase authorizations and the company's common stock listing on the New York Stock Exchange under DVA.
DaVita Inc.’s Chief Compliance Officer James O. Hearty reported an option-style exercise and subsequent stock sale. On May 14, 2026, he exercised 5,784 Stock Appreciation Rights at $110.63 per share, receiving common stock. Of these shares, 3,231 were withheld to pay the base price and 1,117 were withheld to cover tax obligations.
On May 15, 2026, he completed an open-market sale of 15,000 DaVita common shares at a weighted average price of $193.983, within a price range of $193.360–$199.840. Following these transactions, he directly owns 22,389 DaVita common shares.
DaVita Inc. (DVA) notice of proposed sale reports employee RSU vesting entries and a recent sale. The filing lists multiple vested RSU lots by vesting date and quantity and records 2,184 shares sold on 05/06/2026 in the past three months. The listed vesting entries show scheduled cash-settled awards across dates from 02/21/2014 to 05/14/2026.
DaVita Inc. Chief Operating Officer David Paul Maughan reported two open-market stock sales. On May 11, he sold 7,073 shares of DaVita common stock at a weighted average price of $199.149 per share. On May 12, he sold an additional 13,456 shares at a weighted average price of $199.254 per share. After these transactions, he directly owns 94,105 DaVita shares, so he continues to hold a substantial position in the company.
DaVita Inc. submitted a Form 144 notice listing proposed sales of common stock tied to employee equity events. The excerpt itemizes planned dispositions from ESPP purchases and restricted stock vesting with sample lot sizes of 307, 5,711, 165, and 14,346 shares on the dates shown.
DaVita Inc.’s CFO and Treasurer Joel Ackerman reported an open-market sale of 51,471 shares of DaVita common stock. The transaction occurred on May 7, 2026 at a weighted average price of $192.099 per share, with individual sale prices ranging from $191.510 to $192.765. Following this sale, Ackerman directly holds 132,434 shares of DaVita common stock.
DaVita Inc. Chief Compliance Officer James O. Hearty reported an open-market sale of Common Stock. On May 6, 2026, he sold 2,184 shares at $174.87 per share. After this transaction, he directly owned 35,953 shares of DaVita common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025, indicating the trades were scheduled in advance.
DaVita Inc. reported proposed sales of Common Stock under a Form 144 via UBS Financial Services Inc. The filing lists multiple blocks of shares tied to employee equity events, including awards and option exercises on 03/15/2025, 03/15/2024, 09/16/2024, 05/10/2023, and 05/15/2023.
The broker named is UBS Financial Services Inc. and the shares are listed on the NYSE. The filing documents planned dispositions of specific share counts associated with those grant/exercise dates (examples shown below).
DaVita Inc. insider filing shows a large share sale by Berkshire Hathaway–related entities. An entity associated with Berkshire completed an open-market sale of 1,220,376 shares of DaVita common stock at an average price of $149.8429 per share. After this transaction, Berkshire-associated holdings reported in the filing total 28,880,209 DaVita shares, held indirectly.
The filing explains that 13,906,601 of these shares are owned by Government Employees Insurance Company, a Berkshire subsidiary, and 14,973,608 shares are owned by pension plans of Berkshire subsidiaries. Berkshire and Warren E. Buffett disclaim beneficial ownership in certain shares except to the extent of any pecuniary interest.
DaVita Inc. reported higher results for the three months ended March 31, 2026, with total revenues of $3,415.5M versus $3,223.5M a year earlier. Net income attributable to DaVita rose to $197.5M from $162.9M, and diluted EPS increased to $2.87 from $2.00.
U.S. dialysis remained the core business, generating $2,941.7M of revenue and operating income of $506M, while ancillary services produced $498M of revenue and modest operating income of $6M. Consolidated operating income grew to $481.9M from $438.9M.
Operating cash flow strengthened to $320.8M from $180.0M, supporting capital spending of $102.0M and share repurchases of 3.0 million shares for $402.9M. Long-term debt totaled $10,626.3M in principal, and DaVita signed an agreement to buy a roughly $200M minority stake in Elara Caring, pending customary approvals.